Adagene Inc. (FRA:978)

Market Cap	210.96M +217.7%
Revenue (ttm)	6.53M +7,332.8%
Net Income	-15.00M
EPS	-0.32
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10
Open	3.260
Previous Close	3.260
Day's Range	3.260 - 3.260
52-Week Range	1.180 - 3.840
Beta	n/a
RSI	54.92
Earnings Date	Aug 12, 2026

About Adagene

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 128
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 978

Financial Performance

In 2025, Adagene's revenue was $7.67 million, an increase of 7332.76% compared to the previous year's $103,204. Losses were -$17.61 million, -47.32% less than in 2024.

Financial numbers in USD